An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer

Michael S. Gordon*, Francisco Robert, Daniela Matei, David S. Mendelson, Jonathan W. Goldman, E. Gabriela Chiorean, Robert M. Strother, Ben K. Seon, William D. Figg, Cody J. Peer, Delia Alvarez, Bonne J. Adams, Charles P. Theuer, Lee S. Rosen

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

52 Scopus citations

Fingerprint

Dive into the research topics of 'An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences